Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In the Phase 3 BaxHTN study in adults with uncontrolled (uHTN) or resistant (rHTN) hypertension, the selective aldosterone synthase inhibitor, baxdrostat, at 1 and 2 mg/day in addition to background therapy, lowered seated office systolic blood pressure (SBP) by 8.7 and 9.8 mmHg, respectively, vs placebo at 12 weeks. BaxAsia (NCT06344104) has a similar randomised, double-blind design comparing the efficacy and safety of baxdrostat vs placebo in hypertensive patients primarily from Asia. Here, we present the baseline characteristics of participants included in BaxAsia.
Adults aged ≥18 years were eligible if they had: uHTN or rHTN, defined as mean seated SBP between ≥140 and <170 mmHg despite stable treatment with 2 (uHTN) or ≥3 (rHTN) antihypertensive medications (including a diuretic) at maximally tolerated dose; an estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2; and a serum potassium level between ≥3.5 and <5.0 mmol/L. After a 2-week placebo run-in period, participants with a mean seated SBP ≥135 mmHg were randomised 1:1:1 to baxdrostat 1 mg, baxdrostat 2 mg or placebo once daily for a 12-week double-blind period. This was followed by 3 sequential periods: 12-week open-label period (baxdrostat 2 mg); 8-week double-blind randomised withdrawal period (randomised 2:1 to baxdrostat 2 mg or placebo); 20-week open-label period (baxdrostat 2 mg). The primary endpoint is change in seated SBP from baseline to Week 12 with baxdrostat 2 mg vs placebo.
Overall, 666 participants were screened and 326 were randomised; 49.4% had uHTN and 50.6% had rHTN. Mean (standard deviation, SD) age and body mass index were 59.2 (11.5) years and 29.3 (5.3) kg/m2, respectively. Overall, 57.7% were male, 62.3% were Asian and 37.1% were White. Participants were recruited from China mainland (47.9%), Russia (20.6%), Turkey (9.5%), Japan (9.2%), Argentina (4.6%), Australia (3.1%), South Korea (2.1%), Vietnam (1.8%), China Hong Kong (0.9%) and India (0.3%).
At baseline, mean (SD) seated SBP was 149.0 (8.7) mmHg despite treatment with 2–5 antihypertensive medications. Participants with rHTN were on 3 (67.9%), 4 (26.1%) or 5 (6.1%) antihypertensive medications at baseline. Baseline eGFR, serum potassium and sodium levels were 88.2 (17.9) mL/min/1.73 m2, 4.2 (0.4) mmol/L and 140.7 (2.5) mmol/L, respectively. In total, 40.5% of participants had a history of dyslipidaemia, 36.8% obesity, 25.2% type 2 diabetes, 7.1% coronary artery stenosis, 7.4% chronic kidney disease, 4.6% myocardial infarction, 4.6% heart failure and 4.3% stroke. Overall, 99.4% of participants had primary hypertension and 0.6% had secondary hypertension (kidney disease). At baseline, all participants were on diuretic, 96.3% on ACEi, ARB or ARNI, 48.5% on calcium channel blocker, 16.0% on beta blocker and 8.3% on other medications.
Participants randomised in BaxAsia were representative of adults primarily from Asia with uHTN or rHTN with elevated SBP despite multiple antihypertensive medications. A history of dyslipidaemia, type 2 diabetes and/or obesity were the most common comorbidities. BaxAsia will assess the seated office blood pressure-lowering effect and safety of baxdrostat in the study participants.
